6:35 AM
 | 
Mar 22, 2019
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Opsumit improves right ventricular function in PAH patients

Actelion Ltd. said Opsumit macitentan significantly improved right ventricular function and pulmonary vascular resistance at week 26 compared with baseline in the open-label Phase IV REPAIR trial in patients with symptomatic pulmonary arterial hypertension.

The Johnson...

Read the full 160 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >